Compare CPF & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPF | ZVRA |
|---|---|---|
| Founded | 1954 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.5M | 741.9M |
| IPO Year | 2011 | 2015 |
| Metric | CPF | ZVRA |
|---|---|---|
| Price | $35.55 | $12.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $23.00 |
| AVG Volume (30 Days) | 105.6K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | 45.18 | ★ 159.21 |
| EPS | ★ 0.78 | 0.60 |
| Revenue | $51,817,000.00 | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $4.62 | $53.42 |
| P/E Ratio | $45.79 | ★ $21.62 |
| Revenue Growth | 33.81 | ★ 350.91 |
| 52 Week Low | $25.62 | $7.16 |
| 52 Week High | $37.01 | $14.27 |
| Indicator | CPF | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 61.82 |
| Support Level | $33.33 | $8.26 |
| Resistance Level | N/A | $14.27 |
| Average True Range (ATR) | 0.81 | 0.76 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 66.18 | 65.01 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.